Americord Expands Cord Blood Banking Capacity

NEW YORK–(BUSINESS WIRE)–#Americord–Americord, the fastest growing cord blood bank in the country, is
reinforcing its commitment to providing state-of-the-art umbilical cord
blood, cord tissue, and placenta tissue banking to its clients by
securing additional capacity at a second cyropreservation laboratory.

With significantly more resources for processing and storage, Americord
is now positioned for its next phase of growth. The combination of two
world-class facilities allows the company to meet emerging client needs
and accelerates product development for even better patient outcomes.

“As Americord continues to grow, our dedication to clients remains
unchanged,” said CEO Martin Smithmyer. “We have aligned ourselves with
the most innovative labs in the cord blood banking industry to ensure
expanding families receive the best possible products and services.”

Americord has thoroughly vetted both facilities to ensure they meet all
regulatory requirements and conform to Americord’s standards of
operating excellence.

About Americord Registry (“Americord”)

Americord Registry is a leader in the advancement of umbilical cord
blood, cord tissue and placenta tissue banking. Americord collects,
processes, and stores newborn stem cells from umbilical cord blood for
future medical or therapeutic use, including the treatment of more than
80 blood diseases such as sickle cell anemia and leukemia. Founded in
2008, Americord is registered with the FDA and operates in all 50
states. The company’s laboratories are CLIA Certified, accredited by the
AABB and comply with all federal and state guidelines and applicable
licenses. Americord is headquartered in New York, NY. For more
information, visit


Americord Registry
Alysha Bullock, 866­503­6005